A
Andrey A. Komissarov
Researcher at University of Texas Health Science Center at Tyler
Publications - 43
Citations - 578
Andrey A. Komissarov is an academic researcher from University of Texas Health Science Center at Tyler. The author has contributed to research in topics: Plasminogen activator & Plasminogen activator inhibitor-1. The author has an hindex of 14, co-authored 34 publications receiving 466 citations. Previous affiliations of Andrey A. Komissarov include University of Texas System.
Papers
More filters
Journal ArticleDOI
Effects of extracellular DNA on plasminogen activation and fibrinolysis
TL;DR: Extracellular DNA at physiological concentrations may potentiate fibrinolysis by stimulating fibrin-independent plasminogen activation and increases enzyme susceptibility to serpins, and DNA is a macromolecular template that both potentiates and inhibits fibrinelysis.
Journal ArticleDOI
Plasminogen Activator Inhibitor-1 Deficiency Augments Visceral Mesothelial Organization, Intrapleural Coagulation, and Lung Restriction in Mice with Carbon Black/Bleomycin–Induced Pleural Injury
Torry A. Tucker,Ann Jeffers,Alexia Alvarez,Shuzi Owens,Kathleen B. Koenig,Brandon Quaid,Andrey A. Komissarov,Galina Florova,Hema Kothari,Usha R. Pendurthi,L. Vijaya Mohan Rao,Steven Idell +11 more
TL;DR: It is found that a C57Bl/6j mouse model of carbon black/bleomycin injury demonstrates pleural organization resulting in pleural rind formation and PAI-1 regulates CBB-induced pleural injury severity via unrestricted fibrinolysis and cross-talk with coagulation proteases.
Journal ArticleDOI
Intrapleural Adenoviral Delivery of Human Plasminogen Activator Inhibitor–1 Exacerbates Tetracycline-Induced Pleural Injury in Rabbits
Sophia Karandashova,Galina Florova,Ali Azghani,Andrey A. Komissarov,Kathy Koenig,Torry A. Tucker,Timothy Craig Allen,Kris Stewart,Amy R. Tvinnereim,Steven Idell +9 more
TL;DR: Intrapleural fibrinolytic therapy (IPFT) with plasminogen activators was effective in both animals overexpressing hPAI-1 and control animals with tetracycline injury alone, and may be both a biomarker of pleural injury and a molecular target for its treatment.
Journal ArticleDOI
Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits
Galina Florova,Ali Azghani,Sophia Karandashova,Chris Schaefer,Kathleen Koenig,Kris Stewart-Evans,Paul Declerck,Steven Idell,Andrey A. Komissarov +8 more
TL;DR: PAI-1-neutralizing mAbs improved IPFT by increasing the durability of intrapleural PA activity and suggesting a novel, well-tolerated IPFT strategy that is tractable for clinical development.
Journal ArticleDOI
Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites
Hong Long Ji,Runzhen Zhao,Andrey A. Komissarov,Yongchang Chang,Yongfeng Liu,Michael A. Matthay +5 more
TL;DR: In this article, the authors demonstrate multifaceted mechanisms for uPA-mediated up-regulation of ENaC, which form the cellular and molecular rationale for the beneficial effects of urokinase in mitigating mortal pulmonary edema and pleural effusions.